Erku et al. (2020) *Nicotine & Tobacco Research*

Doi: <https://doi.org/10.1093/ntr/ntz046>

Beliefs and self-reported practices of healthcare professionals regarding electronic nicotine delivery systems (ENDS): a mixed-methods systematic review and synthesis

Daniel A Erku (BPharm)¹, Coral E Gartner (PhD)^{2, 3}, Kylie Morphett (PhD)², and Kathryn J Steadman (PhD)¹

¹School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia

²School of Public Health, The University of Queensland, Herston Road, Herston 4006, Queensland, Australia

³Queensland Alliance for Environmental Health Sciences, The University of Queensland, 20 Cornwall Street, Woolloongabba 4102, Queensland, Australia

Email addresses:

Daniel A Erku: d.erku@uq.edu.au

Coral Gartner: c.gartner@uq.edu.au

Kylie Morphett: k.morphett@uq.edu.au

Kathryn Steadman: k.steadman@uq.edu.au

Abstract

Aims:

This review explores the beliefs and practices of healthcare professionals (HCPs) regarding electronic nicotine delivery systems (ENDS), including their views on 1) use as a smoking cessation aid; 2) safety and health risks; 3) regulation; and 4) patient-HCP communications.

Methods:

PubMed, Embase, CINAHL, and PsycINFO were searched to identify articles published since 2003. The Mixed Methods Appraisal Tool (MMAT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklists were employed to assess the quality of studies. Thematic synthesis was employed to analyse qualitative data.

Results:

A total of 45 articles (32 quantitative, 12 qualitative and 1 mixed) were included. There was wide variation regarding beliefs about the efficacy of ENDS as a cessation aid. Although the majority of HCPs believes that ENDS are safer than combustible cigarettes, they also have concern about the short and long-term safety of ENDS, uptake by adolescents, and the potential for ENDS to act as a 'gateway' to smoking cigarettes. Beliefs about ENDS are influenced by media stories and experiences provided by patients. While most HCPs do not proactively recommend ENDS, they are more likely to support ENDS use among patients with smoking related co-morbidities, heavy smokers with previous unsuccessful quit attempts, or patients who express interest in trying them.

Conclusions:

Overall, HCPs hold diverse views about the efficacy of ENDS and expressed wariness over their potential health effects. HCP endorsement of ENDS use seems to depend largely on patient health status, the presence of other competing risk factors and patient preferences

Implication:

While evidence on safety and efficacy of ENDS is emerging, HCPs should be honest with their clients, stating that the long-term safety is not yet established but what is known is that they appear to be a lower risk alternative to cigarettes. Our review highlights a need for further training and

support for HCPs regarding ENDS use, which would enable them to guide their clients in making evidence-based decisions.

Key words: Attitudes, healthcare professionals, practice, ENDS, e-cigarettes, systematic review

INTRODUCTION

Smoking cessation is key to preventing premature mortality and morbidity. Advice from healthcare professionals (HCPs) can increase the success of quit attempts ¹. Smoking cessation guidelines in many countries recommend that HCPs proactively identify smokers and offer support to help them quit ¹⁻³. Although there are approved pharmacological smoking cessation aids (primarily varenicline, bupropion and nicotine replacement therapies [NRT]) ⁴, an increasing number of smokers are using electronic nicotine delivery systems (ENDS), also known as electronic cigarettes or e-cigarettes, as a cessation aid or a lower risk alternative to conventional cigarettes ⁵⁻⁸. The uptake of ENDS globally over the last decade has been rapid. A number of reviews have concluded that vaping is likely to be less harmful than smoking due to the lower levels of toxins in the emissions compared to cigarette smoke ^{9,10}. However, current evidence about the role of ENDS in smoking cessation is mixed and there is debate about whether smokers should be encouraged to use them ¹¹. Opponents urge caution because their long term health effects are unknown and they could be a “gateway” to smoking among young people ^{12,13}. Proponents assert that because ENDS are less harmful than conventional cigarettes ¹⁴, smokers should be encouraged to switch to these products to reduce their health risk. For example, Public Health England included advice about switching from cigarettes to ENDS in its annual Stoptober quit campaign from 2017 ¹⁵.

Many smokers report being interested in receiving information about the safety of ENDS ¹⁶ and are asking their healthcare providers for evidence-based advice about ENDS ¹⁷⁻²⁰. Some countries have updated their smoking cessation guidelines to incorporate advice about ENDS and emerging tobacco products ²¹. Recently, the UK’s National Centre for Smoking Cessation and Training released a briefing for stop smoking services and online training for HCPs on how to incorporate ENDS into smoking cessation clinical practice ^{3,22}. In the US, a number of evidence updates and

practice guidelines have been published for HCPs involved in adolescent health ²³, otolaryngologists ²⁴, primary care providers ²⁵, cardiologists ²⁶ and nurses ²⁷. Unfortunately, these practice guidelines interpreted the current scientific evidence inconsistently and recommendations for or against ENDS **vary**. In the absence of consistent and evidence-based clinical guidelines, HCPs and smoking cessation counsellors may rely on their own beliefs when discussing ENDS with their clients. Thus, it is important to review the current evidence on the beliefs of HCPs about ENDS, to identify their gaps in knowledge and to inform future interventions.

METHODS

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline ²⁸ and the study protocol was registered on PROSPERO (CRD42018088584).

Data sources and search strategy

We searched PubMed, Embase, CINAHL and PsycINFO for studies reporting any of the following: 1) the attitudes of healthcare professionals toward ENDS; 2) beliefs about their efficacy and safety; 3) attitudes towards regulation of ENDS in terms of availability, sale and promotion; and 4) the extent and content of patient-healthcare provider communication about ENDS. We defined HCPs as practitioners who work in all branches of healthcare including medicine, surgery, dentistry, pharmacy, psychology, nursing or allied health professions that have direct contact with their patients/clients. The keywords used in the search strategy were organised to capture key concepts of the subject as: (“Electronic Nicotine Delivery Systems” OR “electronic cigarettes” OR “e- cigarettes” OR “vaping”) AND (“Health Personnel” OR “Healthcare Professional” OR “General Practitioner” OR “Smoking Cessation Counsellor”) and tailored to each database. The search included articles published in all languages since 2003 to cover the literature from when ENDS first entered the market until the third week of September 2018. Forward and backward citation searches of included articles were performed to further locate eligible articles that were not identified in the database search. Details on search terms and the number of records identified are provided in Table S1.

Eligibility screening

Studies were included if they were primary studies (quantitative, qualitative or mixed methods), conducted among HCPs and reported data on at least one of our review objectives listed above (see Figure 1). Studies were excluded if they reported only on the use of ENDS by HCPs, or if the sample was composed only of students who do not treat patients. Conference or dissertation abstracts without the full text available for retrieval were also excluded. All titles and abstracts were screened by DAE to identify those that met the inclusion criteria. A second person (KM) screened 20% of all initial search results to ensure the screening criteria was being accurately and consistently applied. No differences between DAE and KM were identified. All full text articles were screened by two authors (DAE and KM) independently, with no differences identified.

Quality appraisal

Quality appraisal tools were employed for this review to interpret the findings in light of the quality of the included studies, rather than as an inclusion criteria. We employed the Mixed Methods Appraisal Tool (MMAT) ^{29,30} and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklists ³¹ to assess the quality of included studies. For this review, we used the ‘descriptive’ subcategory of MMAT and STROBE for appraising the quantitative articles, and used reporting criteria outlined in MMAT to appraise qualitative and mixed-method studies.

Data extraction and synthesis

Data on study characteristics and findings were recorded in a custom excel spreadsheet. For quantitative studies, study characteristics (publication details, country, study design, sample size etc.) and key findings were extracted. Some items were reported in numerous articles (including perceived efficacy of e-cigarettes as smoking cessation aid, beliefs regarding the health risk and addiction potential of e-cigarettes, potential of e-cigarettes to be a “gateway” to smoking, views on the regulation of e-cigarettes use in public places, as well as recommendation for/against the use of e-cigarettes to clients as a way to quit smoking). Others (e.g., health effect of nicotine) were reported only in one or two studies. Since the included studies differed in terms of study objectives, methodological approach and survey items, conducting a meta-analysis was not appropriate. Therefore, the extracted data was grouped into subcategories based on our review objectives, organized into tables and reported narratively. For qualitative studies, a subset of the data was

double coded independently by two authors (DAE and KM), and disagreement resolved through discussion until consensus was reached. All text included in the “results” section of the remaining articles were coded (by DAE) and analysed using thematic synthesis³². Line by line coding was used to identify recurring patterns and words. We used a combination inductive and deductive approach. While codes were developed relevant to our research aims, line-by-line coding was also conducted to identify emergent themes. Codes were categorized into nine ‘descriptive’ themes (Table 2) according to thematic similarity. These descriptive themes were then combined into more overarching themes for interpretation and discussion. NVivo version 12 was used to assist with the coding process.

RESULTS

After removal of duplicates and publications that did not meet the inclusion criteria, 45 articles were included (see Figure 1), consisting of 32 quantitative cross-sectional studies^{17-20,33-60}, twelve qualitative studies⁶¹⁻⁷² and one mixed methods study⁷³. The studies were conducted between 2013 and 2018 and most were from the United States^{17,19,20,33,35,39,40,42,48,50-54,60,62-64,66-68,70,73} or the UK^{37,38,43,44,55,57,58,61,69,72}. The remainder were conducted in Australia^{34,36,56,59,71}, New Zealand⁶⁵, Belgium⁴¹, Korea⁴⁹, Italy^{18,45} and Greece⁴⁷. A total of 13,548 participants (13,262 from quantitative studies and 292 from qualitative studies; including the mixed-method study) were included. The most commonly included HCPs were general practitioners and specialists (n=20) and smoking cessation counsellors (n=6). Pharmacists (n=3) and nurses (n=1) were the least represented HCPs among the identified studies. Twelve studies included participants from more than one professional role. One article was published in Italian language⁴⁵. We used translation software to translate into English, and checked for coherence by someone whose first language was Italian. Detailed descriptions of study characteristics are shown in Table S2. Most of the quantitative studies (21 out of 30) met 18 or more of the 22 STROBE criteria. All clearly outlined their research questions and target populations. However, they all employed simple convenience (non-probability) sampling, making it difficult to generalize findings beyond the sample. The majority of the qualitative data analyzed in this review came from five studies^{62,64,66,69,70}. The remaining six studies contributed less relevant data because either ENDS were not the sole focus of the study⁶⁷ or the data lacked depth^{61,63,65,68}. In all qualitative studies, data were collected through in-depth interviews, focus groups or both. All studies clearly outlined their research

objectives and defined their data sources (participants and/or recruitment sites). However, there was lack of clarity across many studies in terms of researcher reflexivity, ethical considerations and/or details of interview questions.

Synthesis of quantitative findings

The measurement of perceptions of the safety and effectiveness of ENDS differed between studies. Some studies directly measured relative harm of ENDS by asking “In patients who smoke, ENDS are safer than conventional cigarettes”, with answers possible from “Strongly disagree” to “Strongly agree”^{19,38,49,50,59}. Others stated “ENDS are a safe alternative to conventional cigarettes” with a “Yes/No” option^{39,48}. Some studies also indirectly measured this by asking “In your opinion, which of the following have greater health risk?” Respondents rated the relative safety of different products such as regular tobacco cigarettes, NRTs and varenicline compared to ENDS⁴⁶, or rated the health effects of ENDS, chewing tobacco or snuff/snus compared to regular cigarettes⁵⁴ by selecting an option from “Not at all harmful”, “Moderately harmful” or “Very harmful”.

Beliefs of HCPs toward perceived efficacy of ENDS

Perceived efficacy of ENDS for smoking cessation was reported in 17 of the included quantitative studies (Table 1). Efficacy beliefs varied widely, ranging from 10%⁷³ to 86%⁵⁵ of HCPs who believed that ENDS helped people to quit smoking. For example, 70.9% of smoking cessation practitioners in Italy believed that ENDS could be an effective smoking cessation aid¹⁸. In contrast, two studies conducted among thoracic oncology practitioners in UK and lung cancer specialist physicians in Korea reported a very low proportion with the belief that ENDS are effective for quitting smoking (13.6% and 21.6% respectively)^{38,49}.

Beliefs of HCPs toward perceived risk of ENDS

Four topics that were commonly reported across studies were the perceived relative risk of ENDS compared to cigarettes, health risk of second-hand vapour, addiction potential of ENDS, and potential for ENDS to be a ‘gateway’ to smoking (Table 1). The potential safety of ENDS were compared with combustible cigarettes, non-combustible tobacco products and/or NRTs. HCPs in the majority of the studies (11 out of 12 studies) believed that ENDS were less harmful than cigarettes, but more harmful compared to NRTs⁴⁶. The highest level of agreement that ENDS were safer than cigarettes were reported among HCPs in Flanders (83%),⁴¹, a British thoracic

oncology group (68.5 %) ³⁸ and HCPs in Minnesota (65.5%) ⁴². In contrast, a substantial proportion of lung cancer specialist physicians in Korea (76.7%) believed that ENDS confer a higher health risk than cigarettes ⁴⁹. Similarly, nearly half (46%) of dental health professionals in the US believed that ENDS were as harmful as traditional cigarettes ⁶⁰. Surprisingly in one study, 46% of HCPs wrongly perceived ENDS to be as ‘carcinogenic’ ⁷⁴ and nicotine was believed to have a substantial contribution to lung cancer and other smoking related diseases ⁴¹. Three studies asked whether exposure to secondhand vapour is harmful ^{20,41,46}. About 5% of pediatricians and family medicine physicians in the US ²⁰ and 71% of quitline counselors in the U.S. and Canada ⁴⁶ believed that second-hand aerosol might be harmful. Across studies, the majority of HCPs believed that nicotine containing ENDS are addictive ^{39,41,46,47} and have the potential to be a “gateway” to smoking among youth ^{20,42,49,50,55}.

Views on ENDS regulation

Few studies examined attitudes concerning the regulation of ENDS apart from restrictions on public use and advertising/promoting. The majority of HCPs supported banning ENDS use in public places ^{20,35,41,43,45-49} and ENDS advertising ⁴⁶⁻⁴⁹. HCPs also recommended to have a health warning labels for ENDS ^{48,49} and restrict flavours ^{47,49}.

Six studies examined attitudes towards ENDS sales to minors, ^{38,41,46-49}, with the majority of HCPs across and within the studies unanimously supporting banning sales to minors (e.g., approximately 93% of quitline counsellors in US and Canada ⁴⁶, 73.7% of HCPs in Greece⁴⁷, and 99.5% of lung cancer specialist physicians in Korea) ⁴⁹.

HCP self-reported practice regarding ENDS

Eighteen articles examined patient-provider interactions about ENDS. These studies asked about patient screening, recommendations about use, and requests for advice about ENDS from patients. While the majority of HCPs believed that it is important to discuss ENDS use in clinical practice, some reported that they were uncomfortable talking to patients ^{42,49} about ENDS and believed that discussing ENDS with patients may encourage them to use these products ^{42,49}. Three studies found that while obstetricians or gynecologists screened their patients for smoking^{36,40,54}, few screened for ENDS use.

Even though a large proportion of HCPs have been asked about ENDS by their clients ^{44,46}, few reported that screening and/or counselling tools were in place to record patient ENDS use ⁴⁴. The majority of HCPs across and within the studies reported that they never recommended ENDS to their patients ^{17,33,38,40,41,46-48,51,57,73}. For instance, only 4% of quit line counsellors in the US and Canada ⁴⁶, 6.6% of general practitioners and tobacco counsellors in Belgium ⁴¹ and 4.8% of thoracic oncology practitioners in the UK ³⁸ reported suggesting ENDS to their clients as a smoking cessation aid and/or lower risk alternative to cigarettes. Overall, the guidance provided to patients during the patient-HCP discussion is inconsistent across studies and influenced by their beliefs regarding ENDS. HCPs often advised patients that not much is known about ENDS and therefore did not provide advice to their patients, advised against the use of ENDS, and/or recommend the use of approved smoking cessation aids ^{19,48}.

Based on the limited data, the main source of information regarding ENDS were the media and internet⁶⁰ or patients ^{18,57}. HCPs in majority of studies reported being uninformed regarding ENDS ^{20,38,49} and wanted to see more evidence on the safety profile of ENDS use, the risks of exposure to second-hand aerosol, the role of ENDS in smoking cessation and whether ENDS was a getaway to smoking combustible cigarettes.

Synthesis of qualitative findings

Twelve studies were included in the qualitative data synthesis. Participants included primary care physicians ^{62,66,73}, pediatricians ⁶⁴ and tobacco cessation counsellors ^{61,69}. Some studies included data from more than one type of HCP ^{65,67,68}. Interview guides used across the studies differed to some extent but all studies included questions exploring general knowledge of ENDS and beliefs about their health effects. Example questions included “How do you think ENDS compare to other available tobacco products?” ⁶⁶, and “What are your opinions regarding ENDS and smoking cessation?” ⁶² Some studies also asked about patient-provider communication and clinical practice regarding ENDS (e.g., “Have you ever asked your patients or been asked by your clients about ENDS? If yes, how?”, “Did you ever recommend ENDS to your clients? What is your motivation/reason behind this?”) ⁶⁶. All, except two studies ^{63,65} employed thematic analysis. Across studies, the primary topics of discussion during interviews were their perceived efficacy and safety as well as ‘clinical actions/practices.’ We identified three recurring themes: (1) lack of

knowledge about ENDS and its relative risk; (2) wariness about the potential short- and long-term health effects of ENDS; and (3) willingness to support patients' desire to try ENDS despite feeling wary. The topics and sub-themes identified, along with representative quotes are summarized in Table 2.

Theme 1: HCPs are poorly informed about ENDS and continuum of risk

Although HCPs were aware of ENDS and their main ingredients (such as nicotine and flavouring agents), they lacked knowledge regarding the potential health effects of ENDS, their role in smoking cessation, and current regulations. This lack of knowledge and feeling of being 'uninformed' was reported consistently by HCPs across and within studies.

Preferred information sources and needs

HCPs in most of the studies did not often cite scientific research as a source of information. Rather, their belief regarding ENDS was largely derived from media, advertising, internet, newspaper articles and patient experiences ^{64,71}.

While the content and volume of information retrieved was not explored in detail, findings from some studies suggested that the information in the lay literature negatively influenced HCPs' overall perception regarding ENDS.

"I thought they were an interesting phenomenon originally...I don't really follow the research...just what I come across in the lay literature. There are increasing concerns about what is in that vapor other than just nicotine so I am more concerned now than I was originally... It's just not steam and nicotine, there's more to it." ⁶²

Some HCPs also reported learning about ENDS from their patients ^{64,67}.

"I ask my patients all the time, they teach me." ⁶⁴

HCPs stated that they would feel more confident if the safety profiles of ENDS were determined through rigorous scientific research ^{64,72}. They also expressed that they would be more confident if they had educational resources or official guidelines from their respective peak professional bodies regarding ENDS ⁷² and indicated a need for training/support and guidance.

“I want to see a study like that, that randomizes people to e-cigarettes versus Chantix, versus patches, versus doctors just telling people to quit smoking, and when I see that, then I’ll say it’s an effective means of helping people quit, but there’s no data on that. It has to be studied” ⁶⁶.

Perceived continuum of risk

The perceived risk of ENDS were often compared with cigarettes and NRTs. When contemplating relative risk, participants in the majority of studies believed that ENDS are less harmful than cigarettes^{62-64,66,67,71,72}, but more harmful than NRTs ⁶². ENDS were sometimes perceived to be as bad as cigarettes ⁷³. The difficulty of inferring relative safety in light of the scant and inconclusive scientific literature on the long term safety of ENDS were also discussed by some HCPs ⁷³.

“I think, on general, taken as a whole, they’re safer than smoking, chewing tobacco, pipes, cigars probably” ⁶⁶.

“I think the patch and the gum are safer, there’s no inhaling of anything and in the patch there are no other chemicals that we need to be worried about” ⁶².

While the need for more research was universally recognized by HCPs, some already believe health effects will emerge ⁷¹.

“I don’t think it would necessarily be surprising to find studies later that show that vaping has a greater chance of, you know, inducing lung symptoms in an otherwise healthy person.” ⁶⁴

“This [e-cigarettes] is going to cause lung cancer” ⁶⁴

There were concerns about nicotine addictiveness/toxicity and these influenced judgements about relative risk. Some HCPs asserted that ENDS could potentially confer a higher cardiovascular risk compared to cigarettes due to the nicotine in ENDS.

*“I wouldn’t say its (e-cigarette) safe, because nicotine can make your heart rate go up, and vaso-constrict... So I guess, in certain ways, you could have more harm to the heart than a regular cigarette, perhaps, in certain situations”*⁶⁶.

HCPs in nearly all studies did not endorse ENDS as intrinsically safe. Concerns over creating and/or continuing addiction to nicotine in ENDS and the potential toxicity of nicotine⁶³ were the main reasons cited by HCPs.

*“E-cigarettes still provide nicotine and continue to encourage physiologic addiction to that chemical”*⁷³.

Theme 2: Wariness about the long- and short-term effects of ENDS

Concerns about safety and efficacy

HCPs across different studies had mixed beliefs regarding the role of ENDS in smoking cessation and/or harm reduction^{63,64,68,73}. There were substantial differences in perceived efficacy of ENDS as a quitting aid within the studies. A US study⁷³ reported that over half of family physicians perceived ENDS as a stepping stone to quitting smoking, while an equivalent proportion of physicians asserted that ENDS are not effective for quitting smoking.

*“[E-cigarettes] can be used to taper nicotine just like patches, gum, etc. [They] provide tactile satisfaction that is so much a part of cigarette smoking.”*⁷³.

Overall, HCPs in the majority of the studies were skeptical about the role of ENDS in smoking cessation and/or harm reduction and called for more research to confirm their effectiveness^{62,64,67,68}.

Similarly, HCPs in most of the studies expressed a feeling of wariness about potential long- and short term health effects of ENDS^{61,62,64,72}. For instance, HCPs were concerned about possible cancer risk, exposure to second-hand vapour and involvement of the tobacco industry in ENDS marketing.

*“I’ve heard that there are carcinogens in the exhaled vapors. They cause problems like stimulating kids who have sensitive airways to cough and wheeze.”*⁶⁴

*“The tobacco industry has learned a lot of lessons from their first time around...” “...If their goal is to get nicotine [out] into the public, they did that without the image of a cigarette”*⁶⁴

Addressing the ‘hand-to-mouth’ habit by ENDS was also discussed. While HCPs in some studies indicated that ENDS would help smokers deal with the hand-to-mouth behaviour associated with cigarette smoking, others thought ENDS might create a new addiction⁷², renormalise smoking⁷¹ and/or make it difficult to break the addiction to smoking.

*“And then there’s the psychological process of holding the device and inhaling. To me, inherently, that would not be as good a product to get somebody off cigarettes”*⁶².

The potential health concerns expressed by HCPs appears to differ by speciality. Pulmonologists⁴⁹ were particularly worried about the detrimental effects on the respiratory system while gynaecologists and obstetricians⁵⁴ expressed concerns over the potential harmful effect of nicotine in pregnancy. Paediatricians were primarily concerned about the accidental ingestion and poisoning of children with nicotine-containing e-liquid as well as the potential to be a ‘gateway’ to smoking among adolescents⁶⁴. Similarly, HCPs involved with care of thoracic surgery patients were concerned about the effect of ENDS aerosols and flavours on the respiratory system⁷¹

The potential of youth uptake of ENDS

Advertising of ENDS was often described by HCPs as concerning, as it could encourage young people to try these products, which could create an addiction, possibly leading to more dangerous tobacco products and/or dual use of ENDS and cigarettes^{62,64,70,72}. In addition to youth-friendly flavours and the appealing nature of ENDS, the apparent targeted marketing and advertisement of these products to young people was a major concern raised by HCPs.

*“It’s very appealing to children, because they’re pretty, they’re colorful, [and] they taste good.”*⁶⁴

*“I am most concerned about gateway to other tobacco products and also impact on minors. I think that’s a big one and I’m very, very concerned about that”*⁶².

Theme 3: Patient-healthcare provider communication regarding ENDS

Integrating ENDS screening into routine clinical practice

The qualitative research mirrored quantitative findings that screening for and recording the use of ENDS was seldom incorporated into routine clinical practice ^{64,66,68}. Nonetheless, patient-provider discussion about ENDS was reported to be common ⁶⁴, with patients prompting the discussion by asking their HCPs for guidance and information regarding the safety and efficacy of ENDS for smoking cessation ^{62,64,66}. HCPs in most of the studies reported that the current tobacco-based screening protocols lack a comprehensive and meaningful criteria pertaining to ENDS ^{64,66}. This, coupled with the presence of other competing priorities, makes it difficult to address ENDS use in clinical practice. Furthermore, HCPs pointed out the difficulty of discussing safety concerns with patients who were enthusiastically using ENDS ⁶⁴.

HCPs who were hesitant to probe ENDS use preferred to “wait to see which way the evidence falls, and/or the regulatory agencies fall” ⁷⁰ before recommending and/or documenting ENDS use.

“I will not be planning to do anything until guidelines or regulatory agencies enforce policies to do so.” ⁷⁰

This notion was further explored in a study conducted among stop smoking services in England, where attitudes and engagement of advisors regarding ENDS were reported to be largely influenced by the scientific reports from notable public health organisations such as Public Health England (e.g. the 95% less harmful estimate) and the guidance provided by the National Centre for Smoking Cessation and Training.

“So, as a service I’d say comparatively we were cautious to perhaps some other areas that were a little bit more, I am going to say ‘gung ho’and then as you know Public Health England have come out and endorsed them and really been quite pro-them, and more evidence has come out then, so obviously we, on the back of that, we have been a lot more e-cigarette friendly”⁶⁹

Expectedly, uncertainty about unknown long-term health effects⁷², fear of maintaining addiction to nicotine, the possibility of relapsing to smoking and/or ‘dual use’, absence of medicinal licensing and endorsement from regulatory agencies were cited as barriers for integrating ENDS

into clinical practice ^{69,70}. In the UK, where ENDS use is widely accepted by the public health community, the barriers to integrating ENDS into clinical practice went beyond lack of a medically licensed product and entailed the ‘ethical dilemma’ of engaging with consumer products that are manufactured by tobacco companies. ⁶⁹

Circumstances under which HCPs are willing to recommend ENDS

In a number of studies, HCPs did not proactively recommend ENDS to their clients ^{62,65,66,73}. They stated that recommending products that are not proven to be effective and/or approved by the appropriate regulatory authority would be breaching their “duty of care”. ⁶⁹ Yet, concerns and uncertainties about ENDS use were less prominent for some patient populations. Central to HCPs’ endorsement and/or recommendation of ENDS for smoking cessation or harm reduction were the patient’s health status (presence of smoking related co-morbidities and other risk factors), ⁶⁶, history of previous unsuccessful quit attempts with conventional smoking cessation aids ⁶² and patient preferences for trying ENDS ^{65,67}. In one US study, primary care physicians reported endorsing ENDS for heavy smokers and priority populations with comorbidities, among whom smoking was perceived as an ‘eminent threat’ to their health ⁶⁶.

“The people who are smoking like a pack a day and really chimneys, I’m like, you want anything that you can do that’s an action that gets in the right direction. So I usually am pretty encouraging of it [recommending ENDS] in that setting” ⁶⁶.

“Somebody who comes to me and specifically says, I am thinking of switching then the patient preference would be a factor in this case” ⁶⁶.

Moreover, those who strongly endorsed ENDS leant towards moral discourse and justified their practice as a ‘moral obligation’ to support smokers and socially vulnerable peoples who are attempting to quit through vaping. ⁶⁹ As such, ENDS were perceived as a novel approach ‘to engage the hard to reach groups experiencing health inequality’ and support priority populations with comorbidities such as people with mental health problems. While many HCPs across studies passively support their patients’ use of ENDS, HCPs in some stop smoking services proactively offers ENDS vouchers to clients who attend their clinics. ⁶⁹

DISCUSSION

Principal findings

We systematically collected and synthesized published research on the beliefs and practices of HCPs regarding ENDS. HCPs hold mixed beliefs regarding the role of ENDS in smoking cessation. While the majority believed that ENDS are safer than cigarettes, they also expressed concerns over the short- and long term health effects of ENDS, use by adolescents, and the potential for ENDS to act as a ‘gateway’ to smoking. Qualitative research suggested that the beliefs of HCPs regarding ENDS are influenced by information exposure from media, advertising, internet, newspaper articles and experiences provided by patients. While data were limited in terms of views about ENDS regulation, the majority of HCPs agreed with bans on ENDS advertising, use in public places and sale to minors. In some qualitative studies, HCPs called for more research to occur before legalizing the sale of ENDS as a smoking cessation aid. Screening patients for ENDS use does not appear to be routine practice, but patients sometimes request guidance and information about these products. HCP recommendations about ENDS are largely dependent upon the clients’ tobacco use status (heavy smokers) and health status (co-morbidity), prior unsuccessful quit attempts as well as patient preferences. This review focused only on studies of self-reported practice of HCPs regarding ENDS. However, evidence from the few studies that have examined what patients report about their interactions with HCPs also found that HCPs do not regularly engage in patient-provider discussions regarding ENDS ⁷⁵ despite patient interest in trying these products as quit aids ⁷⁶.

The mixed beliefs of HCPs between studies can partially be explained by the varying regulatory frameworks applied across different countries. HCPs in countries with liberal approaches to the use and marketing of ENDS, such as the UK, have more positive attitudes and provide “e-cigarette friendly” services. The Medicines and Healthcare products Regulatory Authority (MHRA) in the UK adopted a dual regulatory pathway, with ENDS being sold as either a medicinal or a consumer product. ENDS marketed as consumer products in the UK are regulated by the EU Tobacco Product Directive ⁷⁷. In this environment, the National Centre for Smoking Cessation and Training in the UK has published online training for HCPs regarding ENDS and smoking cessation ³.

However, HCPs practicing in more restrictive regulatory environments, such as Australia, reported less engagement with patients regarding ENDS use⁵⁶. The variation in regulatory approaches across different countries also partially explains the observed difference in beliefs regarding ENDS and recommendation of ENDS for smoking cessation.

Implication for research and practice

Since HCPs are a trusted source of health information, practitioners need to be cognizant of the current issues surrounding ENDS. Although there has been an increase in our understanding of ENDS in recent years, the current evidence base for the long-term safety and efficacy of ENDS in smoking cessation is not conclusive. The research evidence suggests that ENDS are unlikely to be without some health risk, but they deliver fewer toxins and carcinogens compared to smoking^{78,79}.

HCPs are currently exposed to a wide array of information regarding ENDS from a variety of sources^{3,22,23,27,80}. The information may promote or discourage ENDS use. HCPs' reliance on media and internet as a source of information is particularly worth mentioning as the information obtained from such sources is not always scientifically verified and emphasises anecdotal experiences. There is a growing body of literature regarding the safety and efficacy of ENDS from highly credible organisations such as Public Health England⁹, The National Academies of Science and Engineering¹⁰, and the Australia Commonwealth Scientific and Industrial Research Organisation (CSIRO)⁸¹. However, these reports are voluminous and our research suggests that HCPs would benefit from a more efficient source of trustworthy information about the latest research on ENDS. One suggestion is providing a regular evidence-based summary of current research peak health bodies and professional organisations. Overall, there is a need to develop and disseminate evidence-based and customized educational intervention packages for HCPs to help them guide their clients in making an informed decision regarding ENDS use. This is particularly important given the low confidence of HCPs in their knowledge of ENDS.

Despite the availability of a range of smoking cessation aids, some smokers prefer ENDS over available approved therapies, including NRTs^{78,82}. A number of reviews now confirm that ENDS are likely to be much less harmful than cigarettes and the use of ENDS by current smokers is more likely to lead to quit attempts, especially with additional behavioural support^{9,10,78}. While evidence on safety and efficacy of ENDS is emerging, HCPs should be honest with their clients, stating that

the long-term safety is not yet established but what is known is that they appear to be a lower risk alternative to cigarettes. It is also essential for clinical practitioners to consider the patient's overall health status and make sensible and individualized recommendations. With this in mind, the use of less harmful products such as ENDS could be regarded as a viable strategy for those smokers unable to quit by other means. It is important that smokers using ENDS as a quit aid are encouraged to stop smoking completely rather than using ENDS as a partial substitute because even low level smoking still confers substantial health risk⁸³. Stopping ENDS use once they are confident of not relapsing to smoking will also minimize any residual health risks associated with vaping.

Our review also highlights some areas in the current literature that warrant further research and attention. As the majority of studies come from either the US (n=21) or UK (n=8), there is a need for evidence from HCPs practicing in other countries, where the regulatory landscape and acceptance of ENDS is different, such as Australia and Canada. There was also little data from some HCPs such as pharmacists, nurses and dentists. Given the role of these HCPs in assisting patients to quit smoking, their perspective regarding ENDS is important. It is also worth noting that only three qualitative studies have been conducted in the UK despite the growth of these products in recent years and their endorsement by public health authorities and peak health bodies such as the UK's Royal College of Physicians. Largely absent from the current literature was a detailed exploration of views of HCPs regarding facilitators and barriers to integrating patient screening for ENDS use into routine clinical practice. The advice given to clients of low socio-economic status regarding ENDS use was rarely explored and few studies reported data on advice given to women during pregnancy^{36,40,54}. Moreover, exploring the perspectives of HCPs regarding their preferred information and uptake of training activities on ENDS is essential if customised educational interventions are to be developed.

Strength and limitations

To the best of our knowledge, this is the first mixed-methods review and synthesis of research on the attitudes and self-reported practices of HCPs regarding ENDS. While we have employed rigorous and accepted approaches²⁹⁻³¹ to present the global data for the first time since ENDS were introduced to the market, our review has some limitations that should be taken into account while interpreting the findings. There are no studies identified from low and middle income countries (LMICs), despite our extensive searches of electronic databases. Hence, our findings

may not adequately present the views of HCPs in these countries. Most of the included studies differed in terms of study objectives, methodological approach and survey items which precluded us from employing meta-analysis. Furthermore, substantial differences between studies in the way perceptions of ENDS were measured makes it difficult to directly compare findings. In a study conducted to compare differences between direct (for example, “compared to conventional cigarettes, is ENDS less harmful, as harmful or more harmful?”) and indirect (for example “...how harmful is using ENDS to one's health?”) measures of ENDS risk perceptions, it was reported that ENDS were more likely to be perceived as less harmful than cigarettes by smokers when employing indirect rather than direct measures ⁸⁴. Currently, there are no standard and validated measures of risk perceptions of ENDS, particularly for HCPs, making the results of many studies on this topics difficult to compare ⁸⁵. Thus, future studies should consider including validating measures of perceived risk of ENDS.

CONCLUSIONS

Overall, HCPs hold diverse views about the efficacy and safety of ENDS use. Most HCPs do not appear to be screening patients for ENDS use, or raising the issue of ENDS in routine clinical practice, despite the desire of patients for guidance and interest in trying these products. HCPbeliefs regarding ENDS largely depended on information exposure from the media and anecdotal experiences provided by patients. HCP endorsement of ENDS as a smoking cessation aid or low risk alternative to combustible cigarettes seems to depend on the patient’s health status and risk factor profile. This review highlights the need for further training and support of HCPs regarding ENDS use, which would enable them to guide their clients in making evidence-based decision.

Funding

DAE was supported by University of Queensland (UQ) Research and Training Scholarship. No other financial support was gained to conduct this study.

Declaration of competing interest

All authors declare that there is no any actual or potential conflict of interest

ACKNOWLEDGMENT

We would like to thank Ms. Christine Dalais for her unreserved professional guidance during electronic database searching.

Legends

Table S1: Full list of databases searched and searching terms used

Table S2: Characteristics of included studies (both quantitative and qualitative)

Table 1: Categories and subcategories of aggregated findings from quantitative data.

Table 2: Themes and illustrative quotes identified during synthesis of the 9 studies containing qualitative data.

Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram

REFERENCES

1. Fiore M. *Treating tobacco use and dependence: 2008 update: Clinical practice guideline*. Diane Publishing; 2008.
2. Zwar N, Richmond R, Borland R, et al. Supporting smoking cessation: a guide for health professionals. Melbourne: The Royal Australian College of General Practitioners, 2011. *Google Scholar* 2014; <https://www.racgp.org.au/guidelines/smokingcessation>. Accessed April 29, 2018.
3. E-cigarettes: a guide for healthcare professionals. 2018; <http://elearning.ncsct.co.uk/e-cigarettes-stage-1>. Accessed April 19, 2018.
4. Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. *Br J Clin Pharmacol*. 2014;77(2):324-336.
5. Pepper JK, Brewer NT. Electronic nicotine delivery system (electronic cigarette) awareness, use, reactions and beliefs: a systematic review. *Tob Control*. 2014;23(5):375-384.
6. Yong H-H, Borland R, Balmford J, et al. Trends in e-cigarette awareness, trial, and use under the different regulatory environments of Australia and the United Kingdom. *Nicotine Tob Res*. 2014;17(10):1203-1211.
7. Yoong SL, Stockings E, Chai LK, et al. Prevalence of electronic nicotine delivery systems (ENDS) use among youth globally: a systematic review and meta-analysis of country level data. *Aust N Z J Public Health*. 2018.
8. Zhu S-H, Zhuang Y-L, Wong S, Cummins SE, Tedeschi GJ. E-cigarette use and associated changes in population smoking cessation: evidence from US current population surveys. *BMJ*. 2017;358:j3262.
9. McNeill A, Brose LS, Calder R, Bauld L, Robson D. Evidence review of e-cigarettes and heated tobacco products 2018. 2018; <https://www.gov.uk/government/publications/e-cigarettes-and-heated-tobacco-products-evidence-review/evidence-review-of-e-cigarettes-and-heated-tobacco-products-2018-executive-summary>. Accessed April 18, 2018.
10. National Academies of Science. Public Health Consequences of E-Cigarettes. 2018; <http://nationalacademies.org/hmd/Reports/2018/public-health-consequences-of-e-cigarettes.aspx>. Accessed April 14, 2018.
11. Glynn TJ. E-cigarettes and the future of tobacco control. *CA Cancer J Clin*. 2014;64(3):164-168.
12. Capewellquestion MMS. Evidence about electronic cigarettes: a foundation built on rock or sand? *BMJ*. 2015:17.
13. Primack BA, Soneji S, Stoolmiller M, Fine MJ, Sargent JD. Progression to traditional cigarette smoking after electronic cigarette use among US adolescents and young adults. *JAMA Pediatr*. 2015;169(11):1018-1023.
14. Wagener TL, Siegel M, Borrelli B. Electronic cigarettes: achieving a balanced perspective. *Addiction*. 2012;107(9):1545-1548.
15. Hawkes N. The mixed messages that led to an e-cigarette shambles. *BMJ*. 2017;358.
16. Wackowski OA, Manderski MTB, Delnevo CD. Smokers' sources of e-cigarette awareness and risk information. *Prev Med Rep*. 2015;2:906-910.
17. Kandra KL, Ranney LM, Lee JGL, Goldstein AO. Physicians' attitudes and use of e-cigarettes as cessation devices, North Carolina, 2013. *PLoS One*. 2014;9(7).
18. Lazuras L, Muzi M, Grano C, Lucidi F. E-cigarettes as smoking cessation aids: a survey among practitioners in Italy. *Int J Public Health*. 2016;61(2):243-248.
19. Nickels AS, Warner DO, Jenkins SM, Tilburt J, Hays JT. Beliefs, Practices, and Self-efficacy of US Physicians Regarding Smoking Cessation and Electronic Cigarettes: A National Survey. *Nicotine Tob Res*. 2017;19(2):197-207.

20. Pepper JK, Gilkey MB, Brewer NT. Physicians' Counseling of Adolescents Regarding E-Cigarette Use. *J Adolesc Health*. 2015;57(6):580-586.
21. National Institute for Health and Clinical Excellence. Stop smoking interventions and services. 2018 update. 2018; <https://www.nice.org.uk/guidance/ng92/chapter/Recommendations#advice-on-ecigarettes>. Accessed May 11, 2018.
22. McEwen Andy MH. Electronic cigarettes: A briefing for stop smoking services. 2016; http://www.ncsct.co.uk/publication_electronic_cigarette_briefing.php. Accessed April 19, 2018.
23. Hildick-Smith GJ, Pesko MF, Shearer L, et al. A practitioner's guide to electronic cigarettes in the adolescent population. *J Adolesc Health*. 2015;57(6):574-579.
24. Biyani S, Derkay CS. E-cigarettes: an update on considerations for the otolaryngologist. *Int J Pediatr Otorhinolaryngol*. 2017;94:14-16.
25. Albert JS. E-Cigarettes: What Primary Care Providers Need to Know. 2016; <https://scholarworks.uvm.edu/cgi/viewcontent.cgi?article=1190&context=fmclerk>. Accessed April 11, 2018.
26. Liberman J, Wann S. E-Cigarettes—What a Practicing Cardiologist Needs to Know. *Am J Cardiol*. 2017;119(4):681-686.
27. Prochnow JA. E-cigarettes: A Practical, Evidence-based Guide for Advanced Practice Nurses. *J Nurse Pract*. 2017;13(7):449-455.
28. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
29. Pluye P, Gagnon M-P, Griffiths F, Johnson-Lafleur J. A scoring system for appraising mixed methods research, and concomitantly appraising qualitative, quantitative and mixed methods primary studies in Mixed Studies Reviews. *Int J Nurs Stud*. 2009;46(4):529-546.
30. Pace R, Pluye P, Bartlett G, et al. Testing the reliability and efficiency of the pilot Mixed Methods Appraisal Tool (MMAT) for systematic mixed studies review. *Int J Nurs Stud*. 2012;49(1):47-53.
31. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *International journal of surgery*. 2014;12(12):1500-1524.
32. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. *BMC Med Res Methodol*. 2008;8(1):45.
33. Egnot E, Jordan K, Elliott JO. Associations with resident physicians' early adoption of electronic cigarettes for smoking cessation. *Postgrad Med J*. 2017;93(1100):319-325.
34. Sharma R, Meurk C, Bell S, Ford P, Gartner C. Australian mental health care practitioners' practices and attitudes for encouraging smoking cessation and tobacco harm reduction in smokers with severe mental illness. *Int J Ment Health Nurs*. 2018;27(1):247-257.
35. Haber LA, Ortiz GM. Clearing the air: Inpatient providers' knowledge, perspectives, and experience with electronic cigarettes. *J Hosp Med*. 2014;9(12):805-807.
36. Gould GS, Zeev YB, Tywman L, et al. Do Clinicians Ask Pregnant Women about Exposures to Tobacco and Cannabis Smoking, Second-Hand-Smoke and E-Cigarettes? An Australian National Cross-Sectional Survey. *Int J Environ Res Public Health*. 2017;14(12).
37. Hiscock R, Goniewicz ML, McEwen A, et al. E-cigarettes: Online survey of UK smoking cessation practitioners. *Tob Induc Dis*. 2014;12(1).
38. Sherratt FC, Newson L, Field JK. Electronic cigarettes: a survey of perceived patient use and attitudes among members of the British thoracic oncology group. *Respir Res*. 2016;17(1):55.
39. Grabigel A, Dilucente D, Wolfe L, McConaha J. Electronic cigarettes: the perceptions of pharmacists and physicians. *Pharmacotherapy*. 2016;36(7):e111.

40. Northrup TF, Klawans MR, Villarreal YR, et al. Family Physicians' Perceived Prevalence, Safety, and Screening for Cigarettes, Marijuana, and Electronic-Nicotine Delivery Systems (ENDS) Use during Pregnancy. *J Am Board Fam Med*. 2017;30(6):743-757.
41. Van Gucht D, Baeyens F. Health professionals in Flanders perceive the potential health risks of vaping as lower than those of smoking but do not recommend using e-cigarettes to their smoking patients. *Harm Reduct J*. 2016;13(1):22.
42. Pepper JK, McRee AL, Gilkey MB. Healthcare providers' beliefs and attitudes about electronic cigarettes and preventive counseling for adolescent patients. *J Adolesc Health*. 2014;54(6):678-683.
43. Pippard BJ, Shipley MD. Healthcare staff attitudes towards the use of electronic cigarettes ('e-cigarettes') compared with a local trust policy. *Perspect Public Health*. 2017;137(4):216-219.
44. Beard E, Brose LS, Brown J, West R, McEwen A. How are the English Stop Smoking Services responding to growth in use of electronic cigarettes? *Patient Educ Couns*. 2014;94(2):276-281.
45. De Clemente A, Frigerio S, Clari M, et al. Il fenomeno sigaretta elettronica: utilizzo, conoscenze e opinioni degli operatori sanitari nella realtà italiana. *La Medicina del Lavoro*. 2016;107(3):213-222.
46. Cummins S, Leischow S, Bailey L, et al. Knowledge and beliefs about electronic cigarettes among quitline cessation staff. *Addict Behav*. 2016;60:78-83.
47. Moysidou A, Farsalinos KE, Voudris V, Merakou K, Kourea K, Barbouni A. Knowledge and perceptions about nicotine, nicotine replacement therapies and electronic cigarettes among healthcare professionals in Greece. *Int J Environ Res Public Health*. 2016;13(5).
48. Kanchustambham V, Saladi S, Rodrigues J, Fernandes H, Patolia S, Santosh S. The knowledge, concerns and healthcare practices among physicians regarding electronic cigarettes. *J Community Hosp Intern Med Perspect*. 2017;7(3):144-150.
49. Shin DW, Kim YI, Kim SJ, et al. Lung cancer specialist physicians' attitudes towards e-cigarettes: A nationwide survey. *PLoS One*. 2017;12(2):e0172568.
50. Geletko KW, Myers K, Brownstein N, et al. Medical Residents' and Practicing Physicians' e-Cigarette Knowledge and Patient Screening Activities: Do They Differ? *Health Serv Res Manag Epidemiol*. 2016;3:2333392816678493.
51. Steinberg MB, Giovenco DP, Delnevo CD. Patient-physician communication regarding electronic cigarettes. *Prev Med Rep*. 2015;2:96-98.
52. Baldassarri SR, Chupp GL, Leone FT, Warren GW, Toll BA. Practise patterns and perceptions of chest health care providers on electronic cigarette use: An in-depth discussion and report of survey results. *J Smok Cessat*. 2017;No Pagination Specified-No Pagination Specified.
53. Ridner SL, Keith RJ, Walker KL, Hart JL, Robertson SE. Primary Care Nurse Practitioners' Perceptions of the Use of E-Cigarettes. *J Nurse Pract*. 2017;13(6):e283-e286.
54. England LJ, Anderson BL, Tong VTK, et al. Screening practices and attitudes of obstetricians-gynecologists toward new and emerging tobacco products. *Am J Obstet Gynecol*. 2014;211(6):695.e691-695.e697.
55. Marques Gomes ACN, Nabhani-Gebara S, Kayyali R, Buonocore F, Calabrese G. Survey of community pharmacists' perception of electronic cigarettes in London. *BMJ Open*. 2016;6(11).
56. Bell SK, Mena G, Dean J, Boyd M, Gilks C, Gartner C. Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes. *Drug Alcohol Depend*. 2017;177:67-70.
57. Hiscock R, Bauld L, Arnott D, Dockrell M, Ross L, McEwen A. Views from the coalface: What do english stop smoking service personnel think about E-cigarettes? *Int J Environ Res Public Health*. 2015;12(12):16157-16167.

58. Mughal F, Rashid A, Jawad M. Tobacco and electronic cigarette products: awareness, cessation attitudes, and behaviours among general practitioners. *Prim Health Care Res Dev.* 2018;1-5.
59. Erku DA, Gartner CE, Do JT, Morphet K, Steadman KJ. Electronic nicotine delivery systems (e-cigarettes) as a smoking cessation aid: A survey among pharmacy staff in Queensland, Australia. *Addict Behav.* 2018.
60. Isett KR, Rosenblum S, Barna JA, Hicks D, Gilbert GH, Melkers J. Missed Opportunities for Detecting Alternative Nicotine Product Use in Youth: Data From the National Dental Practice–Based Research Network. *J Adolesc Health.* 2018;63(5):587-593.
61. Tamimi N. Knowledge, attitudes and beliefs towards e-cigarettes among e-cigarette users and stop smoking advisors in South East England: a qualitative study. *Prim Health Care Res Dev.* 2018;19(2):189-196.
62. Singh B, Hrywna M, Wackowski OA, Delnevo CD, Jane Lewis M, Steinberg MB. "Knowledge, recommendation, and beliefs of e-cigarettes among physicians involved in tobacco cessation: A qualitative study". *Prev Med Rep.* 2017;8:25-29.
63. Brown-Johnson CG, Burbank A, Daza EJ, et al. Online Patient–Provider E-cigarette Consultations: Perceptions of Safety and Harm. *Am J Prev Med.* 2016;51(6):882-889.
64. Gorzkowski JA, Whitmore RM, Kaseeska KR, Brishke JK, Klein JD. Pediatrician Knowledge, Attitudes, and Practice Related to Electronic Cigarettes. *J Adolesc Health.* 2016;59(1):81-86.
65. Fraser T, Chee N, Laugesen M. Perspectives of New Zealand health professionals and smokers on e-cigarettes. *N Z Med J.* 2016;129(1441):98-100.
66. El-Shahawy O, Brown R, Elston Lafata J. Primary Care Physicians' Beliefs and Practices Regarding E-Cigarette Use by Patients Who Smoke: A Qualitative Assessment. *Int J Environ Res Public Health.* 2016;13(5).
67. Bascombe TM, Scott KN, Ballard D, Smith SA, Thompson W, Berg CJ. Primary healthcare provider knowledge, beliefs and clinic-based practices regarding alternative tobacco products and marijuana: a qualitative study. *Health Educ Res.* 2016;31(3):375-383.
68. Hiratsuka VY, Avey JP, Trinidad SB, Beans JA, Robinson RF. Views on electronic cigarette use in tobacco screening and cessation in an Alaska Native healthcare setting. *Int J Circumpolar Health.* 2015;74:27794.
69. Farrimond H, Abraham C. Developing E-cigarette friendly smoking cessation services in England: staff perspectives. *Harm Reduct J.* 2018;15(1):38.
70. Hurst S, Conway M. Exploring Physician Attitudes Regarding Electronic Documentation of E-cigarette Use: A Qualitative Study. *Tobacco use insights.* 2018;11:1179173X18782879.
71. Luxton N, Shih P, Rahman M. Electronic Cigarettes and Smoking Cessation in the Perioperative Period of Cardiothoracic Surgery: Views of Australian Clinicians. *Int J Environ Res Public Health.* 2018;15(11):2481.
72. Stepney M, Aveyard P, Begh R. GPs' and nurses' perceptions of electronic cigarettes in England: a qualitative interview study. *Br J Gen Pract.* 2018;bjgp18X699821.
73. Ofei-Dodoo S, Kellerman R, Nilsen K, Nutting R, Lewis D. Family Physicians' Perceptions of Electronic Cigarettes in Tobacco Use Counseling. *J Am Board Fam Med.* 2017;30(4):448-459.
74. VanDevanter N, Zhou S, Katigbak C, Naegle M, Sherman S, Weitzman M. Knowledge, beliefs, behaviors, and social norms related to use of alternative tobacco products among undergraduate and graduate nursing students in an urban U.S. university setting. *J Nurs Scholarsh.* 2016;48(2):147-153.
75. Drouin O, McMillen RC, Klein JD, Winickoff JP. E-Cigarette Advice to Patients From Physicians and Dentists in the United States. *Am J Health Promot.* 2017;0890117117710876.

76. Chen L-S, Baker T, Brownson RC, et al. Smoking cessation and electronic cigarettes in community mental health centers: Patient and provider perspectives. *Community Ment Health J.* 2017;53(6):695-702.
77. The National Archives. Tobacco and Related Products Regulations 2016; <http://www.legislation.gov.uk/ukxi/2016/507/contents/made>. Accessed March 23, 2018.
78. Royal College of Physicians. Nicotine without smoke—tobacco harm reduction. *Royal College of Physicians* 2016; <https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction-0>. Accessed April 21, 2018.
79. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control.* 2013;tobaccocontrol-2012-050859.
80. Essenmacher C, Naegle M, Baird C, et al. Electronic Nicotine Delivery Systems (ENDS): What Nurses Need to Know. *J Am Psychiatr Nurses Assoc.* 2017:1078390317733802.
81. Byrne S, Brindal E, Williams G, et al. E-cigarettes, smoking and health. *A Literature Review Update Australia: CSIRO.* 2018.
82. Steinberg MB, Zimmermann MH, Delnevo CD, et al. E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices. *J Gen Intern Med.* 2014;29(11):1444-1450.
83. Bjartveit K, Tverdal A. Health consequences of smoking 1–4 cigarettes per day. *Tob Control.* 2005;14(5):315-320.
84. Wackowski OA, Manderski MBT, Delnevo CD. Comparison of direct and indirect measures of e-cigarette risk perceptions. *Tob Regul Sci.* 2016;2(1):38-43.
85. Kaufman AR, Suls JM, Klein WM. Communicating tobacco product harm: Compared to what? *Addict Behav.* 2016;52:123-125.

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram

Table 1. Categories and subcategories of aggregated findings (measured in four or more studies) for the studies (n=32) that collected quantitative data.

Category	Subcategories	Example measures	References measuring category
Attitude/ belief	Safety and efficacy	“ENDS are an effective quitting aid”	17-19,34,38,39,41,45-50,52,53,55,56,73
		“ENDS are lower risk/safer than conventional cigarettes”	19,38,40-42,46,47,49,50,53,54,59
		“Nicotine containing ENDS are addictive”	39,41,46,47
		“Exposure to secondhand ENDS vapor is harmful”	20,41,46
		“ENDS could be a “gateway” to other tobacco use”	20,41,42,48-50,55
	Regulation	“The use of ENDS in public places should be banned”	20,35,41,43,45-49
		“ENDS advertising should be banned”	46-49
		“Sales of ENDS to minors/youngsters should be banned”	20,41,46-49

Practices	Patient-provider discussion	“My patients/clients ask me about ENDS”	17-20,46,48
	Recommendation	“I recommend ENDS to my patients/clients as a smoking cessation aid”	17,19,33,38,40,41,46-48,51,57,73

Table 2. Themes and illustrative quotes identified during synthesis of the 12 studies containing qualitative data.

Analytical themes	Descriptive themes	Illustrative quotes	References
Knowledge and risk perception	Beliefs toward efficacy of ENDS as smoking cessation aid	<p><i>“They [e-cigarettes] can be good stepping stone towards quitting smoking”</i> ⁶³.</p> <p><i>“There are lots of different ways to try to quit, I know some people use [e-cigarettes], but since you’re still doing the smoking action, it might not lead to quitting.”</i> ⁶⁴.</p>	63,64,68,73
	Information sources and needs	<p><i>“I ask my patients all the time, they teach me.”</i> ⁶⁴</p> <p><i>“I want to see a study like that, that randomizes people to e-cigarettes versus Chantix, versus patches, versus doctors just telling people to quit smoking...”</i> ⁶⁶.</p>	62,64,66,67,69
	Uncertainty and lack of evidence	<p><i>“[there] are not enough data on outcomes to recommend e-cigarettes.”</i> <i>“there needs to be more studies that are larger and randomized trials to conclude benefit....”</i> ⁷³.</p>	61,62,64,66,67,73
	Perceived continuum	<p><i>“I think, on general, taken as a whole, they’re safer than smoking,</i></p>	62-64,66,67

of risk

chewing tobacco, pipes, cigars probably”⁶⁶.

“While we cannot say they are safe, we can say that they are safer than smoking tobacco”⁶³.

Wariness over short- and long-term safety	Concerns over the potential health effect of ENDS	<i>“I am most concerned about gateway to other tobacco products and also impact on minors. I think that's a big one and I'm very, very concerned about that.”⁶².</i>	62-64,66,73
		<i>“[I have] concern about effects of heated vapor.” “[There is] no proven benefit with uncontrolled liquids”⁷³.</i>	
	Uptake of ENDS by adolescents	<i>“I am most concerned about gateway to other tobacco products and also impact on minors. I think that's a big one and I'm very, very concerned about that”⁶².</i>	62,64,70
Clinical action/practice	‘Ask’/routine screening	<i>“I don’t ask specifically about smokeless tobacco, chewable tobacco, e-cigarettes. It’s generally just ‘Do you smoke?’ or ‘Were you a smoker in the past?’ ...”⁶⁶.</i>	64,66,68
	‘Advise’/patient-provider discussion	<i>“I’ve had questions [about e-cigarettes] come up recently, but I</i>	62,64,66

think it'll come up more and more."

⁶⁴.

'Act'/recommendation *"...I'm not looking to promote e-
cigarettes but I would not disapprove
of it especially if they have tried
other products and have not
succeeded."* ⁶².

62,64-67,73